Genomictree Inc.
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect … Read more
Genomictree Inc. (228760) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.021x
Based on the latest financial reports, Genomictree Inc. (228760) has a cash flow conversion efficiency ratio of -0.021x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.42 Billion) by net assets (₩115.95 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genomictree Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Genomictree Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genomictree Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genomictree Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Turners Automotive Group Ltd
AU:TRA
|
-0.102x |
|
Jinan High tech Development Co Ltd
SHG:600807
|
-0.013x |
|
Upstream Bio, Inc.
NASDAQ:UPB
|
-0.059x |
|
Jw Pharmac
KO:001060
|
0.132x |
|
Gruvaktiebolaget Viscaria
ST:VISC
|
-0.021x |
|
Jyothy Labs Limited
NSE:JYOTHYLAB
|
0.137x |
|
Beijing Haohan Data Technology Co. Ltd. A
SHG:688292
|
N/A |
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
0.031x |
Annual Cash Flow Conversion Efficiency for Genomictree Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Genomictree Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩124.32 Billion | ₩-13.63 Billion | -0.110x | -26.02% |
| 2023-12-31 | ₩125.03 Billion | ₩-10.88 Billion | -0.087x | -317.38% |
| 2022-12-31 | ₩107.05 Billion | ₩4.29 Billion | 0.040x | +160.38% |
| 2021-12-31 | ₩115.10 Billion | ₩-7.63 Billion | -0.066x | +38.01% |
| 2020-12-31 | ₩95.26 Billion | ₩-10.19 Billion | -0.107x | -- |